Clinical Trial Billing: Beginner Checklist

Clinical trial billing compliance is the discipline of making sure every item and service in a clinical trial protocol is billed to the correct payer — Medicare or another insurer, the trial sponsor, or the patient — and never to more than one of them at once. For someone new to research administration, the topic touches Medicare coverage rules, sponsor contracts, and federal fraud law all at once, which makes it easy to get lost. This page is a practical, beginner-level checklist that walks through the core steps in order and links out to CASRAI’s deeper guides on each piece.

Three companion CASRAI resources cover the specialist detail behind each checklist item in full: Medicare Coverage Analysis for Clinical Trials: The Complete Process (the end-to-end MCA workflow), Medicare Clinical Trial Policy (NCD 310.1) (the underlying Medicare coverage rule), and False Claims Act Liability in Clinical Trial Billing (what happens when billing compliance fails). Use this checklist as the orientation; use those three for the procedural depth.

Why this matters before you touch a single claim

Billing the same clinical trial service to both Medicare and the trial sponsor is the single most common fact pattern behind clinical-trial-billing False Claims Act enforcement — a provider generally cannot collect payment twice for the same item. Two publicly documented settlements illustrate the pattern: University of Alabama at Birmingham paid $3.39 million in 2005 to resolve allegations that included double-billing Medicare and a trial sponsor for the same clinical trial services, and Emory University paid $1.5 million in 2013 over allegations that its Winship Cancer Institute billed Medicare and Medicaid for oncology trial services the sponsor had already agreed, and in some cases already paid, to cover. Neither institution set out to defraud anyone — both cases trace back to billing processes that weren’t rigorously tied to a coverage analysis. See False Claims Act Liability in Clinical Trial Billing for the full detail on both cases and the qui tam mechanics involved.

The beginner’s checklist

Work through these steps roughly in order, before and during trial conduct:

1. Determine whether the trial is a Medicare “qualifying clinical trial”

Not every study qualifies for Medicare’s routine-costs coverage. Under CMS National Coverage Determination (NCD) 310.1, a trial generally qualifies if its subject and purpose fall within a Medicare benefit category, it has therapeutic intent, and it meets at least one “deeming” criterion — including funding or endorsement by NIH, or by another CMS-recognized federal agency (VA, DOD, CDC, AHRQ, CMS itself), or conduct under an FDA Investigational New Drug (IND) application. See Medicare Clinical Trial Policy (NCD 310.1) for the full qualifying-criteria test and Medicare Coverage Determinations: NCD vs LCD Explained for how NCDs work as a coverage mechanism generally.

2. Complete a Medicare Coverage Analysis (MCA) before the trial activates

An MCA is the line-by-line billing-compliance review that goes through the protocol and assigns every visit, test, and procedure to exactly one payer category. It is the step that should happen before a trial opens to enrollment, not after billing questions come up. The full walkthrough of who performs an MCA, what documents feed into it, and how it’s kept current is in Medicare Coverage Analysis for Clinical Trials: The Complete Process.

3. Know the three payer categories cold

Every billable item in a clinical trial protocol falls into one of three buckets:

Routine costs (Medicare/insurer-billable) — care a patient would have received anyway as part of standard treatment, regardless of the trial (a standard-of-care scan, management of the underlying condition, a routine follow-up visit).
Research costs (sponsor-billable) — items that exist only because the protocol requires them: the investigational drug or device, extra research-only labs or imaging, protocol-mandated visits beyond the standard-of-care schedule.
Patient responsibility — the normal copayment, coinsurance, or deductible that would apply to a routine-cost item under the patient’s own coverage, unless the sponsor has separately agreed to absorb it.

Getting this three-way split right, item by item, is the entire point of the MCA in step 2.

4. Build (and actually use) the billing grid

The output of an MCA is usually a document called a billing grid, coverage analysis grid, or billing calendar — a visit-by-visit, procedure-by-procedure table showing which payer covers each item. This grid, not the protocol and not the informed consent form, is what an institution’s billing office and clinical trial management system should actually be built to follow. If the grid isn’t the thing front-line billing staff check before submitting a claim, the coverage analysis exists on paper only.

5. Apply the correct claim-level billing flags

For institutional Medicare claims tied to a qualifying clinical trial, billing staff need to know three claim-level requirements: Condition Code 30 (flagging the claim as containing routine costs billed alongside a qualifying clinical trial), the ICD-10 diagnosis code Z00.6, and the trial’s 8-digit NCT number reported in the designated claim field. On outpatient and professional claims, HCPCS modifiers Q1 (a routine service furnished in connection with an approved research study) and Q0 (the investigational item or service itself) are added at the line-item level. See Condition Code 30 for the full mechanics of where each of these fields goes on a claim.

6. Keep the billing grid aligned with the clinical trial agreement budget

The coverage analysis and the sponsor’s clinical trial agreement (CTA) budget need to agree on which party pays for which item — a mismatch between the two is exactly how double-billing happens. See Clinical Trial Agreement (CTA) for what the budget section of a CTA typically covers, and Clinical Trial Budget Example: A Line-Item Walkthrough for what a real line-item budget looks like next to a coverage analysis.

7. Re-review the coverage analysis after every protocol amendment

A protocol amendment that adds, removes, or changes a visit or procedure can shift an item from one payer category to another. An MCA that was accurate at activation can go stale the moment the protocol changes, so a beginner-level rule of thumb is: no amendment goes into effect operationally until the coverage analysis and billing grid have been reviewed against it.

8. Know the common pitfalls that create False Claims Act exposure

The billing errors that most often escalate into compliance and legal exposure are:

Double-billing — billing Medicare (or another insurer) and the sponsor for the same item. This is the core fact pattern behind both settlements cited above.
No MCA, or an MCA never actually consulted by billing staff — a coverage analysis that exists as a document but isn’t wired into the billing workflow provides no real protection.
Missing claim-level flags — omitting Condition Code 30, the Z00.6 diagnosis code, or the NCT number on an otherwise-correct claim can misrepresent a research-related service as ordinary care.
Stale coverage analyses after an amendment — billing against an outdated grid that no longer reflects the current protocol.
Misclassifying screen-failure or non-qualifying-trial costs — billing routine-cost rules to a trial that never met NCD 310.1’s qualifying criteria in the first place.

For how these errors translate into actual enforcement risk — including the qui tam relator mechanism that has driven most real clinical-trial-billing settlements — see False Claims Act Liability in Clinical Trial Billing.

Who typically owns each step

Practices vary by institution, but a common division of labor looks like: the Clinical Trials Office (CTO) or a dedicated coverage-analysis team performs the MCA and maintains the billing grid; the principal investigator and study team confirm which visits and procedures actually occurred against the grid; a billing compliance office applies the correct claim-level codes and modifiers and monitors for double-billing; and the trial’s finance or contracts staff keep the CTA budget synchronized with the grid. See Clinical Trials Office (CTO) for more on how this function is typically structured.

Frequently asked questions

Is a Medicare Coverage Analysis required for every clinical trial?

Generally, any trial with billable patient-care services should have a coverage analysis completed before activation, even if no Medicare beneficiaries are expected to enroll at the outset — enrollment plans can change, and the analysis is also what protects against double-billing other insurers, not just Medicare specifically.

What’s the difference between a billing grid and a clinical trial budget?

The billing grid (the MCA’s output) determines which payer covers each item under Medicare coverage rules and the trial’s own design. The CTA budget determines how much the sponsor pays the site for the items assigned to the sponsor. The two documents need to agree with each other, but they answer different questions — see Clinical Trial Budget Example: A Line-Item Walkthrough.

What happens if a billing error is found after claims have already gone out?

Institutions typically self-report and refund improperly billed amounts once an error is identified, which materially reduces False Claims Act exposure compared to letting an error persist or be found externally. The specifics of how liability and relator incentives work are covered in False Claims Act Liability in Clinical Trial Billing.

Does this checklist apply outside the United States?

No — NCD 310.1, Condition Code 30, and the qui tam False Claims Act mechanism are all specific to the US Medicare and federal fraud-law framework. Institutions operating clinical trials in other jurisdictions need to work from that jurisdiction’s own public-payer coverage and billing-compliance rules.

Clinical Trial Billing Compliance: A Beginner’s Checklist